≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Thyroid crisis or storm

DOID EFO Endpoint Browser PheWeb

E4_THYCRISIS

Hyperthyroidism: Overactivity of the thyroid gland resulting in overproduction of thyroid hormone and increased metabolic rate. Causes include diffuse hyperplasia of the thyroid gland (Graves' disease), single nodule in the thyroid gland, and thyroiditis. The symptoms are related to the increased metabolic rate and include weight loss, fatigue, heat intolerance, excessive sweating, diarrhea, tachycardia, insomnia, muscle weakness, and tremor.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — E05.5
  • Cause of death: ICD-10 — E05.5

2 out of 7 registries used, show all original rules.

89

4. Check minimum number of events

None

89

5. Include endpoints

None

89

6. Filter based on genotype QC (FinnGen only)

85

Control definitions (FinnGen only)

Control exclude
E4_THYROID

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
E05
Name in latin
Crisis thyreotoxica

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 550 428 119
Only index persons 515 401 114
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.00
Only index persons 0.01 0.01 0.00
Median age at first event (years)
Whole population 50.42 49.11 55.48
Only index persons 49.42 47.76 55.28

-FinnGen-

Key figures

All Female Male
Number of individuals 85 67 18
Unadjusted period prevalence (%) 0.02 0.02 0.01
Median age at first event (years) 49.20 48.15 53.12

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
89
Matched controls
890
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H03AA01
ATC
levothyroxine sodium; systemic
624.0
160.0
78
10
E05.5
ICD-10 Finland
Thyroid crisis or storm
+∞
120.1
86
*
H03BB01
ATC
carbimazole; oral
2304.1
96.1
76
*
E05.0
ICD-10 Finland
Thyrotoxicosis with diffuse goitre
+∞
96.0
74
*
E05.9
ICD-10 Finland
Thyrotoxicosis, unspecified
+∞
59.1
50
*
BAA60
NOMESCO Finland
Total thyroidectomy
+∞
49.7
43
*
104
Kela drug reimbursment
Thyroid insufficiency
831.5
48.1
43
*
E89.01
ICD-10 Finland
Postsurgical hypothyroidism
+∞
34.7
31
*
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
190.7
27.3
27
*
H06.2*E05.9
ICD-10 Finland
Dysthyroid exophthalmos
+∞
25.2
23
*
E03
ICD-10 Finland
Other hypothyroidism
192.4
16.0
16
*
E03.89
ICD-10 Finland
Other specified hypothyroidism
88.8
14.0
15
*
E89.00
ICD-10 Finland
Postirradiation hypothyroidism
+∞
13.9
13
*
E05.2
ICD-10 Finland
Thyrotoxicosis with toxic multinodular goitre
+∞
13.9
13
*
C07AA05
ATC
propranolol; systemic
5.3
13.4
41
124
E05
ICD-10 Finland
Thyrotoxicosis [hyperthyroidism]
+∞
11.7
11
*
H062, E050,
ICD-10 Finland
+∞
11.7
11
*
T86
ICPC
Hypothyroidism/myxoedema
+∞
10.6
10
*
BA1AE
NOMESCO Finland
Thyroiid ultrasound examination
55.7
8.9
10
*
E03.80
ICD-10 Finland
Hypothyroidism caused by autoimmune thyroiditis
+∞
7.4
7
*
T85
ICPC
Hyperthyroidism/thyrotoxicosis
+∞
7.4
7
*
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
15.4
7.1
11
8
O99.2
ICD-10 Finland
Endocrine, nutritional and metabolic diseases complicating pregnancy, childbirth and the puerperium
75.0
6.5
7
*
H05.2
ICD-10 Finland
Exophthalmic conditions
+∞
6.3
6
*

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Outpatient Visit
OP [9202]
1.4e+00
2.3e+00
2.3e+00
5.5e+00
2.3e+00
2.4e+00
1.9e+00
cases:87.64%
controls:64.04%
cases:86.52%
controls:40.34%
cases:50.56%
controls:9.66%
cases:62.92%
controls:0.67%
cases:52.81%
controls:10.11%
cases:88.64%
controls:40.91%
cases:95.18%
controls:74.94%
78
570
11
320
77
359
12
531
45
86
44
804
56
6
33
884
47
90
42
800
78
360
10
520
79
637
4
213
Endocrinology
46 [38004485]
3.1e+00
3.8e+00
—
1.0e+50
—
3.9e+00
2.7e+00
cases:25.84%
controls:1.57%
cases:43.82%
controls:1.69%
—
—
cases:17.98%
controls:0.00%
—
—
cases:50.00%
controls:1.93%
cases:34.94%
controls:3.41%
23
14
66
876
39
15
50
875
—
16
0
73
890
—
44
17
44
863
29
29
54
821
Internal Medicine
11 [38004456]
1.3e+00
2.3e+00
2.8e+00
—
2.8e+00
2.2e+00
1.2e+00
cases:48.31%
controls:19.89%
cases:44.94%
controls:7.75%
cases:19.10%
controls:1.35%
—
—
cases:19.10%
controls:1.35%
cases:39.77%
controls:6.70%
cases:40.96%
controls:17.06%
43
177
46
713
40
69
49
821
17
12
72
878
—
17
12
72
878
35
59
53
821
34
145
49
705
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
9.1e-01
1.7e+00
3.3e+00
1.0e+50
3.4e+00
2.2e+00
1.3e+00
cases:16.85%
controls:7.53%
cases:21.35%
controls:4.94%
cases:15.73%
controls:0.67%
cases:6.74%
controls:0.00%
cases:14.61%
controls:0.56%
cases:35.23%
controls:5.68%
cases:51.81%
controls:21.88%
15
67
74
823
19
44
70
846
14
6
75
884
6
0
83
890
13
5
76
885
31
50
57
830
43
186
40
664
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
8.4e-01
1.4e+00
3.1e+00
—
2.9e+00
1.9e+00
9.4e-01
cases:22.47%
controls:11.12%
cases:25.84%
controls:7.75%
cases:16.85%
controls:0.90%
—
—
cases:16.85%
controls:1.12%
cases:36.36%
controls:7.95%
cases:53.01%
controls:30.59%
20
99
69
791
23
69
66
821
15
8
74
882
—
15
10
74
880
32
70
56
810
44
260
39
590
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
9.6e-01
1.2e+00
2.1e+00
—
2.1e+00
1.4e+00
5.7e-01
cases:11.24%
controls:4.61%
cases:14.61%
controls:4.72%
cases:7.87%
controls:1.01%
—
—
cases:10.11%
controls:1.35%
cases:17.05%
controls:4.77%
cases:20.48%
controls:12.71%
10
41
79
849
13
42
76
848
7
9
82
881
—
9
12
80
878
15
42
73
838
17
108
66
742
Otolaryngology
4 [38004449]
6.0e-01
9.6e-01
2.2e+00
1.0e+50
2.5e+00
1.9e+00
8.7e-01
cases:11.24%
controls:6.52%
cases:6.74%
controls:2.70%
cases:6.74%
controls:0.79%
cases:6.74%
controls:0.00%
cases:6.74%
controls:0.56%
cases:14.77%
controls:2.50%
cases:20.48%
controls:9.76%
10
58
79
832
6
24
83
866
6
7
83
883
6
0
83
890
6
5
83
885
13
22
75
858
17
83
66
767
Pharmacy visit
OMOP4822462 [581458]
8.8e-01
2.5e+00
8.1e-01
1.6e+00
1.1e+00
2.3e+00
1.0e+50
cases:96.63%
controls:92.25%
cases:97.75%
controls:78.65%
cases:58.43%
controls:38.54%
cases:8.99%
controls:1.91%
cases:65.17%
controls:39.33%
cases:97.73%
controls:81.25%
cases:100.00%
controls:96.59%
86
821
3
69
87
700
2
190
52
343
37
547
8
17
81
873
58
350
31
540
86
715
2
165
83
821
0
29
Outpatient Hospital
22 [8756]
6.2e-01
1.1e+00
—
—
2.5e+00
1.5e+00
1.0e+00
cases:39.33%
controls:25.84%
cases:22.47%
controls:8.65%
—
—
—
—
cases:10.11%
controls:0.90%
cases:25.00%
controls:7.05%
cases:36.14%
controls:17.06%
35
230
54
660
20
77
69
813
—
—
9
8
80
882
22
62
66
818
30
145
53
705
Ophthalmology
18 [38004463]
1.2e+00
1.6e+00
—
—
—
2.1e+00
1.2e+00
cases:25.84%
controls:9.44%
cases:15.73%
controls:3.60%
—
—
—
—
—
—
cases:20.45%
controls:3.18%
cases:32.53%
controls:12.71%
23
84
66
806
14
32
75
858
—
—
—
18
28
70
852
27
108
56
742
Supplier / Service Provider
OMOP5117446 [33004]
—
-4.0e-02
—
—
—
2.4e+00
3.4e+00
—
—
cases:8.99%
controls:9.33%
—
—
—
—
—
—
cases:5.68%
controls:0.57%
cases:18.07%
controls:0.71%
—
8
83
81
807
—
—
—
5
5
83
875
15
6
68
844
Inpatient Hospital
21 [8717]
6.4e-01
1.2e+00
1.2e+00
—
2.5e+00
1.4e+00
6.0e-01
cases:48.31%
controls:32.92%
cases:28.09%
controls:10.79%
cases:7.87%
controls:2.58%
—
—
cases:14.61%
controls:1.35%
cases:28.41%
controls:9.20%
cases:38.55%
controls:25.65%
43
293
46
597
25
96
64
794
7
23
82
867
—
13
12
76
878
25
81
63
799
32
218
51
632
Medical doctor
Z2221 [2001311556]
1.3e+00
2.1e+00
—
—
-1.0e+50
1.7e+00
1.5e+00
cases:17.98%
controls:5.51%
cases:13.48%
controls:1.91%
—
—
—
—
cases:0.00%
controls:0.56%
cases:7.95%
controls:1.59%
cases:14.46%
controls:3.76%
16
49
73
841
12
17
77
873
—
—
0
5
89
885
7
14
81
866
12
32
71
818
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
7.6e-01
1.2e+00
2.4e+00
—
2.2e+00
8.5e-01
7.8e-01
cases:7.87%
controls:3.82%
cases:10.11%
controls:3.15%
cases:7.87%
controls:0.79%
—
—
cases:7.87%
controls:0.90%
cases:10.23%
controls:4.66%
cases:21.69%
controls:11.29%
7
34
82
856
9
28
80
862
7
7
82
883
—
7
8
82
882
9
41
79
839
18
96
65
754
calcium (different salts in combination); oral
A12AA20 [21600872]
1.3e-01
8.6e-01
—
—
1.8e+00
1.4e+00
1.0e+00
cases:7.87%
controls:6.97%
cases:12.36%
controls:5.62%
—
—
—
—
cases:10.11%
controls:1.80%
cases:21.59%
controls:6.14%
cases:24.10%
controls:10.12%
7
62
82
828
11
50
78
840
—
—
9
16
80
874
19
54
69
826
20
86
63
764
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
4.7e-01
5.7e-01
1.8e+00
1.0e+50
2.3e+00
3.1e-01
4.4e-01
cases:21.35%
controls:14.49%
cases:17.98%
controls:11.01%
cases:11.24%
controls:2.13%
cases:10.11%
controls:0.00%
cases:13.48%
controls:1.57%
cases:17.05%
controls:13.07%
cases:44.58%
controls:34.24%
19
129
70
761
16
98
73
792
10
19
79
871
9
0
80
890
12
14
77
876
15
115
73
765
37
291
46
559
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
8.1e-01
9.3e-01
2.1e+00
—
1.9e+00
6.8e-01
6.5e-01
cases:14.61%
controls:7.08%
cases:15.73%
controls:6.85%
cases:6.74%
controls:0.90%
—
—
cases:10.11%
controls:1.57%
cases:13.64%
controls:7.39%
cases:31.33%
controls:19.18%
13
63
76
827
14
61
75
829
6
8
83
882
—
9
14
80
876
12
65
76
815
26
163
57
687
Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma
14928-6 [3026989]
—
—
1.0e+50
1.0e+50
1.0e+50
—
3.9e+00
—
—
—
—
cases:10.11%
controls:0.00%
cases:5.62%
controls:0.00%
cases:12.36%
controls:0.00%
—
—
cases:28.92%
controls:0.82%
—
—
9
0
80
890
5
0
84
890
11
0
78
890
—
24
7
59
843
Atrial fibrillation and flutter
I48 [45596206]
1.4e+00
1.9e+00
—
1.0e+50
—
1.9e+00
7.9e-01
cases:10.11%
controls:2.58%
cases:11.24%
controls:1.91%
—
—
cases:6.74%
controls:0.00%
—
—
cases:10.23%
controls:1.59%
cases:7.23%
controls:3.41%
9
23
80
867
10
17
79
873
—
6
0
83
890
—
9
14
79
866
6
29
77
821
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
5.1e-01
4.2e-01
1.8e+00
—
1.9e+00
4.2e-01
3.3e-01
cases:21.35%
controls:14.04%
cases:19.10%
controls:13.48%
cases:12.36%
controls:2.36%
—
—
cases:15.73%
controls:2.58%
cases:22.73%
controls:16.14%
cases:48.19%
controls:40.00%
19
125
70
765
17
120
72
770
11
21
78
869
—
14
23
75
867
20
142
68
738
40
340
43
510
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
8.4e-01
9.0e-01
1.9e+00
1.0e+50
1.8e+00
8.1e-01
9.0e-02
cases:19.10%
controls:9.21%
cases:19.10%
controls:8.76%
cases:12.36%
controls:2.13%
cases:8.99%
controls:0.00%
cases:15.73%
controls:2.92%
cases:22.73%
controls:11.59%
cases:32.53%
controls:30.59%
17
82
72
808
17
78
72
812
11
19
78
871
8
0
81
890
14
26
75
864
20
102
68
778
27
260
56
590
Scheduled procedure
ZXD10 [2001311387]
1.1e+00
1.8e+00
—
—
—
1.7e+00
1.5e+00
cases:13.48%
controls:5.06%
cases:10.11%
controls:1.80%
—
—
—
—
—
—
cases:7.95%
controls:1.59%
cases:13.25%
controls:3.18%
12
45
77
845
9
16
80
874
—
—
—
7
14
81
866
11
27
72
823
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
3.4e-01
4.2e-01
1.6e+00
—
1.7e+00
6.3e-01
5.0e-01
cases:19.10%
controls:14.38%
cases:20.22%
controls:14.27%
cases:11.24%
controls:2.47%
—
—
cases:14.61%
controls:2.92%
cases:27.27%
controls:16.59%
cases:49.40%
controls:37.29%
17
128
72
762
18
127
71
763
10
22
79
868
—
13
26
76
864
24
146
64
734
41
317
42
533
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
3.5e-01
4.9e-01
1.6e+00
—
1.7e+00
6.9e-01
4.8e-01
cases:19.10%
controls:14.27%
cases:21.35%
controls:14.27%
cases:11.24%
controls:2.47%
—
—
cases:14.61%
controls:3.03%
cases:28.41%
controls:16.59%
cases:49.40%
controls:37.65%
17
127
72
763
19
127
70
763
10
22
79
868
—
13
27
76
863
25
146
63
734
41
320
42
530
Leukocytes [#/volume] in Blood
26464-8 [3010813]
3.5e-01
4.7e-01
1.5e+00
—
1.6e+00
4.8e-01
2.9e-01
cases:24.72%
controls:18.76%
cases:25.84%
controls:17.87%
cases:16.85%
controls:4.38%
—
—
cases:19.10%
controls:4.49%
cases:29.55%
controls:20.68%
cases:53.01%
controls:45.76%
22
167
67
723
23
159
66
731
15
39
74
851
—
17
40
72
850
26
182
62
698
44
389
39
461
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
3.5e-01
4.1e-01
1.4e+00
—
1.6e+00
4.8e-01
2.9e-01
cases:24.72%
controls:18.76%
cases:24.72%
controls:17.87%
cases:15.73%
controls:4.38%
—
—
cases:19.10%
controls:4.49%
cases:29.55%
controls:20.68%
cases:53.01%
controls:45.76%
22
167
67
723
22
159
67
731
14
39
75
851
—
17
40
72
850
26
182
62
698
44
389
39
461
MCH [Entitic mass]
28539-5 [3035941]
3.6e-01
4.1e-01
1.4e+00
—
1.6e+00
4.8e-01
2.9e-01
cases:24.72%
controls:18.65%
cases:24.72%
controls:17.87%
cases:15.73%
controls:4.38%
—
—
cases:19.10%
controls:4.49%
cases:29.55%
controls:20.68%
cases:53.01%
controls:45.76%
22
166
67
724
22
159
67
731
14
39
75
851
—
17
40
72
850
26
182
62
698
44
389
39
461
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
3.5e-01
4.1e-01
1.4e+00
—
1.6e+00
4.8e-01
2.9e-01
cases:24.72%
controls:18.76%
cases:24.72%
controls:17.87%
cases:15.73%
controls:4.38%
—
—
cases:19.10%
controls:4.49%
cases:29.55%
controls:20.57%
cases:53.01%
controls:45.76%
22
167
67
723
22
159
67
731
14
39
75
851
—
17
40
72
850
26
181
62
699
44
389
39
461
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
3.5e-01
4.1e-01
1.4e+00
—
1.6e+00
4.8e-01
2.9e-01
cases:24.72%
controls:18.76%
cases:24.72%
controls:17.87%
cases:15.73%
controls:4.38%
—
—
cases:19.10%
controls:4.49%
cases:29.55%
controls:20.68%
cases:53.01%
controls:45.76%
22
167
67
723
22
159
67
731
14
39
75
851
—
17
40
72
850
26
182
62
698
44
389
39
461
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
3.5e-01
4.1e-01
1.4e+00
—
1.6e+00
4.8e-01
2.9e-01
cases:24.72%
controls:18.76%
cases:24.72%
controls:17.87%
cases:15.73%
controls:4.38%
—
—
cases:19.10%
controls:4.49%
cases:29.55%
controls:20.68%
cases:53.01%
controls:45.76%
22
167
67
723
22
159
67
731
14
39
75
851
—
17
40
72
850
26
182
62
698
44
389
39
461
Platelets [#/volume] in Blood
26515-7 [3007461]
3.6e-01
3.4e-01
1.4e+00
—
1.6e+00
4.8e-01
2.5e-01
cases:24.72%
controls:18.65%
cases:23.60%
controls:17.98%
cases:15.73%
controls:4.38%
—
—
cases:19.10%
controls:4.61%
cases:29.55%
controls:20.68%
cases:51.81%
controls:45.65%
22
166
67
724
21
160
68
730
14
39
75
851
—
17
41
72
849
26
182
62
698
43
388
40
462
Intravenous general anesthesia
WX404 [2001310807]
—
—
—
—
—
1.8e+00
2.9e+00
—
—
—
—
—
—
—
—
—
—
cases:5.68%
controls:1.02%
cases:9.64%
controls:0.59%
—
—
—
—
—
5
9
83
871
8
5
75
845
Case Management Agency
251B00000X [38004193]
2.3e-01
1.0e-01
5.7e-01
2.6e+00
2.8e-01
5.5e-01
7.5e-02
cases:55.06%
controls:49.44%
cases:43.82%
controls:41.35%
cases:23.60%
controls:14.83%
cases:11.24%
controls:0.90%
cases:19.10%
controls:15.17%
cases:59.09%
controls:45.45%
cases:73.49%
controls:72.00%
49
440
40
450
39
368
50
522
21
132
68
758
10
8
79
882
17
135
72
755
52
400
36
480
61
612
22
238
Day surgery
ZXD20 [2001311388]
1.3e+00
—
—
—
—
—
2.6e+00
cases:5.62%
controls:1.57%
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:0.59%
5
14
84
876
—
—
—
—
—
6
5
77
845
Laboratory Visit
OMOP4822461 [32036]
2.5e-01
4.3e-01
9.7e-01
—
1.6e+00
5.3e-01
1.8e-01
cases:28.09%
controls:23.26%
cases:31.46%
controls:23.03%
cases:21.35%
controls:9.33%
—
—
cases:25.84%
controls:6.74%
cases:38.64%
controls:27.05%
cases:55.42%
controls:50.82%
25
207
64
683
28
205
61
685
19
83
70
807
—
23
60
66
830
34
238
54
642
46
432
37
418
propranolol; oral, parenteral
C07AA05 [21601670]
1.0e+00
2.4e+00
—
—
—
1.2e+00
8.5e-01
cases:12.36%
controls:4.72%
cases:22.47%
controls:2.47%
—
—
—
—
—
—
cases:7.95%
controls:2.50%
cases:12.05%
controls:5.53%
11
42
78
848
20
22
69
868
—
—
—
7
22
81
858
10
47
73
803
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
8.4e-01
6.4e-01
—
—
2.4e+00
9.3e-01
5.6e-01
cases:6.74%
controls:3.03%
cases:5.62%
controls:3.03%
—
—
—
—
cases:6.74%
controls:0.67%
cases:7.95%
controls:3.30%
cases:18.07%
controls:11.18%
6
27
83
863
5
27
84
863
—
—
6
6
83
884
7
29
81
851
15
95
68
755
Basophils/Leukocytes in Blood
30180-4 [3022096]
9.6e-01
8.3e-01
—
—
2.4e+00
1.2e+00
2.4e-01
cases:7.87%
controls:3.15%
cases:7.87%
controls:3.60%
—
—
—
—
cases:6.74%
controls:0.67%
cases:10.23%
controls:3.30%
cases:14.46%
controls:11.76%
7
28
82
862
7
32
82
858
—
—
6
6
83
884
9
29
79
851
12
100
71
750
Monocytes/Leukocytes in Blood
26485-3 [3019069]
9.6e-01
9.4e-01
—
—
2.4e+00
1.2e+00
3.2e-01
cases:7.87%
controls:3.15%
cases:8.99%
controls:3.71%
—
—
—
—
cases:6.74%
controls:0.67%
cases:10.23%
controls:3.30%
cases:15.66%
controls:11.88%
7
28
82
862
8
33
81
857
—
—
6
6
83
884
9
29
79
851
13
101
70
749
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
6.0e-01
9.6e-01
2.4e+00
—
2.0e+00
7.6e-01
8.2e-01
cases:5.62%
controls:3.15%
cases:6.74%
controls:2.70%
cases:6.74%
controls:0.67%
—
—
cases:5.62%
controls:0.79%
cases:7.95%
controls:3.86%
cases:19.28%
controls:9.53%
5
28
84
862
6
24
83
866
6
6
83
884
—
5
7
84
883
7
34
81
846
16
81
67
769
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
8.6e-01
8.8e-01
—
—
2.4e+00
1.2e+00
3.1e-01
cases:7.87%
controls:3.48%
cases:8.99%
controls:3.93%
—
—
—
—
cases:6.74%
controls:0.67%
cases:10.23%
controls:3.41%
cases:15.66%
controls:12.00%
7
31
82
859
8
35
81
855
—
—
6
6
83
884
9
30
79
850
13
102
70
748
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
9.6e-01
8.0e-01
—
—
2.4e+00
1.2e+00
2.4e-01
cases:7.87%
controls:3.15%
cases:7.87%
controls:3.71%
—
—
—
—
cases:6.74%
controls:0.67%
cases:10.23%
controls:3.30%
cases:14.46%
controls:11.76%
7
28
82
862
7
33
82
857
—
—
6
6
83
884
9
29
79
851
12
100
71
750
General Practice
1 [38004446]
5.4e-01
2.3e-01
2.2e+00
—
—
—
5.5e-01
cases:16.85%
controls:10.56%
cases:5.62%
controls:4.49%
cases:6.74%
controls:0.79%
—
—
—
—
—
—
cases:19.28%
controls:12.12%
15
94
74
796
5
40
84
850
6
7
83
883
—
—
—
16
103
67
747
INR in Blood by Coagulation assay
34714-6 [3032080]
4.0e-01
1.1e+00
—
—
2.1e+00
5.7e-01
1.8e-01
cases:5.62%
controls:3.82%
cases:8.99%
controls:3.03%
—
—
—
—
cases:6.74%
controls:0.90%
cases:6.82%
controls:3.98%
cases:12.05%
controls:10.24%
5
34
84
856
8
27
81
863
—
—
6
8
83
882
6
35
82
845
10
87
73
763
More than one and less than three hours
ZXE10 [2001311401]
6.9e-01
1.9e+00
—
—
—
1.7e+00
1.3e+00
cases:8.99%
controls:4.72%
cases:10.11%
controls:1.57%
—
—
—
—
—
—
cases:5.68%
controls:1.14%
cases:9.64%
controls:2.82%
8
42
81
848
9
14
80
876
—
—
—
5
10
83
870
8
24
75
826
CBC panel - Blood by Automated count
58410-2 [40761511]
3.7e-01
2.9e-01
1.3e+00
—
1.9e+00
6.4e-01
1.9e-01
cases:20.22%
controls:14.94%
cases:17.98%
controls:14.04%
cases:10.11%
controls:3.03%
—
—
cases:17.98%
controls:3.03%
cases:25.00%
controls:15.00%
cases:42.17%
controls:37.53%
18
133
71
757
16
125
73
765
9
27
80
863
—
16
27
73
863
22
132
66
748
35
319
48
531
General anesthesia, balanced
WX408 [2001310808]
7.1e-01
1.9e+00
—
—
—
2.2e+00
7.1e-01
cases:8.99%
controls:4.61%
cases:8.99%
controls:1.46%
—
—
—
—
—
—
cases:5.68%
controls:0.68%
cases:6.02%
controls:3.06%
8
41
81
849
8
13
81
877
—
—
—
5
6
83
874
5
26
78
824
pantoprazole; oral, parenteral
A02BC02 [21600097]
4.7e-01
5.8e-01
—
—
1.9e+00
5.7e-01
5.9e-01
cases:16.85%
controls:11.24%
cases:12.36%
controls:7.30%
—
—
—
—
cases:10.11%
controls:1.69%
cases:13.64%
controls:8.18%
cases:26.51%
controls:16.71%
15
100
74
790
11
65
78
825
—
—
9
15
80
875
12
72
76
808
22
142
61
708
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
2.3e-01
4.1e-01
1.1e+00
—
1.8e+00
5.0e-01
3.2e-01
cases:19.10%
controls:15.73%
cases:22.47%
controls:16.07%
cases:10.11%
controls:3.60%
—
—
cases:16.85%
controls:3.15%
cases:27.27%
controls:18.52%
cases:49.40%
controls:41.53%
17
140
72
750
20
143
69
747
9
32
80
858
—
15
28
74
862
24
163
64
717
41
353
42
497
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
4.7e-01
6.0e-01
1.6e+00
—
1.6e+00
6.2e-01
6.4e-01
cases:12.36%
controls:8.09%
cases:15.73%
controls:9.33%
cases:8.99%
controls:2.02%
—
—
cases:10.11%
controls:2.13%
cases:18.18%
controls:10.68%
cases:43.37%
controls:28.82%
11
72
78
818
14
83
75
807
8
18
81
872
—
9
19
80
871
16
94
72
786
36
245
47
605
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
6.8e-01
5.3e-01
1.5e+00
1.0e+50
1.3e+00
4.4e-01
2.2e-01
cases:23.60%
controls:13.48%
cases:20.22%
controls:13.03%
cases:12.36%
controls:3.03%
cases:6.74%
controls:0.00%
cases:11.24%
controls:3.37%
cases:21.59%
controls:15.00%
cases:40.96%
controls:35.76%
21
120
68
770
18
116
71
774
11
27
78
863
6
0
83
890
10
30
79
860
19
132
69
748
34
304
49
546
General Surgery
2 [38004447]
4.5e-01
8.8e-01
—
1.0e+50
—
1.5e+00
5.7e-01
cases:24.72%
controls:17.30%
cases:14.61%
controls:6.63%
—
—
cases:7.87%
controls:0.00%
—
—
cases:14.77%
controls:3.86%
cases:21.69%
controls:13.53%
22
154
67
736
13
59
76
831
—
7
0
82
890
—
13
34
75
846
18
115
65
735
desloratadine; oral
R06AX27 [21603526]
1.3e+00
—
—
—
—
1.1e+00
—
cases:13.48%
controls:3.93%
—
—
—
—
—
—
—
—
cases:6.82%
controls:2.27%
—
—
12
35
77
855
—
—
—
—
6
20
82
860
—
12 lead EKG panel
34534-8 [3044889]
3.9e-01
1.3e+00
—
—
—
1.1e-01
4.7e-01
cases:11.24%
controls:7.87%
cases:12.36%
controls:3.60%
—
—
—
—
—
—
cases:6.82%
controls:6.14%
cases:25.30%
controls:17.53%
10
70
79
820
11
32
78
858
—
—
—
6
54
82
826
21
149
62
701
bisoprolol; oral
C07AB07 [21601689]
8.2e-01
1.3e+00
5.0e-01
—
1.1e+00
9.3e-01
5.4e-01
cases:22.47%
controls:11.35%
cases:29.21%
controls:10.00%
cases:5.62%
controls:3.48%
—
—
cases:10.11%
controls:3.48%
cases:21.59%
controls:9.77%
cases:21.69%
controls:13.88%
20
101
69
789
26
89
63
801
5
31
84
859
—
9
31
80
859
19
86
69
794
18
118
65
732
One hour or less
ZXE00 [2001311394]
1.2e+00
1.2e+00
—
—
—
1.2e+00
1.1e+00
cases:17.98%
controls:6.29%
cases:5.62%
controls:1.69%
—
—
—
—
—
—
cases:5.68%
controls:1.70%
cases:12.05%
controls:4.24%
16
56
73
834
5
15
84
875
—
—
—
5
15
83
865
10
36
73
814
azithromycin; oral, parenteral
J01FA10 [21602978]
7.0e-01
—
-1.0e+50
—
—
7.2e-01
1.1e+00
cases:17.98%
controls:9.78%
—
—
cases:0.00%
controls:0.56%
—
—
—
—
cases:5.68%
controls:2.84%
cases:16.87%
controls:6.12%
16
87
73
803
—
0
5
89
885
—
—
5
25
83
855
14
52
69
798
Cardiology
6 [38004451]
2.6e-01
9.6e-01
—
—
—
1.2e+00
1.1e+00
cases:7.87%
controls:6.18%
cases:7.87%
controls:3.15%
—
—
—
—
—
—
cases:9.09%
controls:2.95%
cases:21.69%
controls:8.82%
7
55
82
835
7
28
82
862
—
—
—
8
26
80
854
18
75
65
775
cefalexin; oral
J01DB01 [21602870]
7.3e-01
1.0e+00
-1.0e+50
—
—
6.0e-01
4.6e-01
cases:43.82%
controls:27.42%
cases:21.35%
controls:9.10%
cases:0.00%
controls:0.90%
—
—
—
—
cases:13.64%
controls:7.95%
cases:36.14%
controls:26.35%
39
244
50
646
19
81
70
809
0
8
89
882
—
—
12
70
76
810
30
224
53
626
Emergency Room Visit
ER [9203]
9.3e-01
7.1e-01
1.7e+00
1.0e+50
—
3.1e-01
6.8e-01
cases:57.30%
controls:34.61%
cases:23.60%
controls:13.15%
cases:7.87%
controls:1.46%
cases:17.98%
controls:0.00%
—
—
cases:13.64%
controls:10.34%
cases:44.58%
controls:28.94%
51
308
38
582
21
117
68
773
7
13
82
877
16
0
73
890
—
12
91
76
789
37
246
46
604
influenza, inactivated, split virus or surface antigen
J07BB02 [21601335]
—
0.0e+00
-1.0e+50
—
-1.0e+50
1.7e-01
7.0e-02
—
—
cases:5.62%
controls:5.62%
cases:0.00%
controls:0.90%
—
—
cases:0.00%
controls:0.67%
cases:7.95%
controls:6.82%
cases:25.30%
controls:24.00%
—
5
50
84
840
0
8
89
882
—
0
6
89
884
7
60
81
820
21
204
62
646
azelastine; nasal
R01AC03 [21605035]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
2.9e-01
cases:0.00%
controls:2.02%
cases:0.00%
controls:0.79%
—
—
—
—
—
—
cases:0.00%
controls:1.14%
cases:7.23%
controls:5.53%
0
18
89
872
0
7
89
883
—
—
—
0
10
88
870
6
47
77
803
Palliative care
Z51.5 [45547323]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
5
83
845
phenylephrine, combinations
R01BA53 [21603214]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
0
6
89
884
—
—
—
0
6
88
874
—
Planned health check-up monitoring, health check-up performed based on individual need
SPAT1317 [2001700418]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
0
5
88
875
—
Other physical therapy
Z50.1 [45600331]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
0
5
89
885
—
—
—
—
0
7
83
843
Complement C4 [Mass/volume] in Serum or Plasma
4498-2 [3017766]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
5
83
845
Acute vaginitis
N76.0 [45543891]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
0
8
83
842
Bacteria [Presence] in Urine
87829-8 [36304419]
—
—
—
—
—
—
4.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:4.12%
—
—
—
—
—
—
5
35
78
815
Calprotectin [Mass/mass] in Stool
38445-3 [3048689]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
0
9
89
881
—
—
—
0
8
88
872
—
Spirometry at the office
SPAT1059 [2001700160]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
0
9
89
881
—
—
—
—
—
0
7
83
843
ipratropium bromide; inhalant
R03BB01 [21603293]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
5
83
845
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:1.41%
—
—
—
—
—
—
5
12
78
838
lovastatin; oral
C10AA02 [21601857]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
0
6
89
884
—
—
—
—
0
5
88
875
—
rofecoxib; oral
M01AH02 [21603993]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
89
879
—
—
—
—
—
—
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
3.4e-01
-2.6e-01
-1.0e+50
—
—
-4.4e-02
1.2e-01
cases:15.73%
controls:11.69%
cases:7.87%
controls:10.00%
cases:0.00%
controls:1.80%
—
—
—
—
cases:11.36%
controls:11.82%
cases:38.55%
controls:35.76%
14
104
75
786
7
89
82
801
0
16
89
874
—
—
10
104
78
776
32
304
51
546
Upper gastrointestinal surgery
106 [44777669]
4.8e-01
—
—
—
—
1.2e+00
9.3e-01
cases:10.11%
controls:6.52%
—
—
—
—
—
—
—
—
cases:7.95%
controls:2.50%
cases:15.66%
controls:6.82%
9
58
80
832
—
—
—
—
7
22
81
858
13
58
70
792
After-cataract
H26.4 [45600893]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
0
7
89
883
—
—
—
—
—
0
5
83
845
Periodontal treatment by dental hygienist
SDE02 [2001310350]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
0
7
89
883
—
—
—
0
6
88
874
—
Elevated blood-pressure reading, without diagnosis of hypertension
R03.0 [45553712]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
6
83
844
Moderate depressive episode without somatic syndrome
F32.10 [2000501980]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
0
6
89
884
—
—
—
—
0
5
88
875
—
levocabastine
S01GX02 [21605086]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
89
881
—
—
—
—
—
—
lactulose; oral
A06AD11 [21600571]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
0
6
89
884
—
—
—
0
8
88
872
—
Contraception female other
W14 [2002001214]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
89
884
—
—
—
—
—
—
Glaucoma suspect
H40.0 [45567051]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
0
5
88
875
—
Gastro-oesophageal reflux disease with oesophagitis
K21.0 [45543296]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
89
885
—
—
—
—
—
—
Leukocytes [Presence] in Urine
33052-2 [3045414]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
0
8
83
842
Initiation and monitoring of IV fluid therapy
SPAT1083 [2001700184]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
89
885
—
—
—
—
—
—
Joint ultrasound examination not elsewhere classified
NK4XE [2001308469]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
0
10
83
840
acrivastine; oral
R06AX18 [21603518]
9.5e-01
—
—
—
—
—
7.0e-01
cases:12.36%
controls:5.17%
—
—
—
—
—
—
—
—
—
—
cases:14.46%
controls:7.76%
11
46
78
844
—
—
—
—
—
12
66
71
784
Presence of coronary angioplasty implant and graft
Z95.5 [45542496]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
89
885
—
—
—
—
—
—
Home Visit
OMOP4822459 [581476]
4.0e-01
—
—
-1.0e+50
—
1.2e+00
3.8e-01
cases:5.62%
controls:3.82%
—
—
—
—
cases:0.00%
controls:0.79%
—
—
cases:5.68%
controls:1.82%
cases:9.64%
controls:6.82%
5
34
84
856
—
—
0
7
89
883
—
5
16
83
864
8
58
75
792
Seropositive rheumatoid arthritis
M05 [45606038]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
5
83
845
Abdominal ultrasound examination
JN3AE [2001305555]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.76%
—
—
—
—
—
—
0
15
83
835
clonazepam; oral, parenteral
N03AE01 [21604415]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
0
6
89
884
—
—
—
—
—
chloramphenicol
S03AA08 [21605197]
9.1e-01
—
—
—
—
—
5.8e-01
cases:8.99%
controls:3.82%
—
—
—
—
—
—
—
—
—
—
cases:13.25%
controls:7.88%
8
34
81
856
—
—
—
—
—
11
67
72
783
Eye symptom/complaint other
F29 [2002000412]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.29%
—
—
—
—
—
—
0
11
83
839
Hepatitis B virus core IgM Ab [Presence] in Serum
31204-1 [3013527]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
6
83
844
formoterol and budesonide
R03AK07 [21603281]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.01%
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
0
9
89
881
0
6
89
884
—
—
—
—
—
medroxyprogesterone; oral, parenteral
G03DA02 [21602540]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
0
8
83
842
Streptococcus pyogenes Ag [Presence] in Throat
18481-2 [3033319]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
89
878
—
—
—
—
—
—
Gas panel - Venous blood
24339-4 [3000991]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
0
5
88
875
—
Cervical spine CT examination
NA1AD [2001306982]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
5
83
845
insulin detemir; parenteral
A10AE05 [21600740]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.69%
cases:0.00%
controls:1.24%
—
—
—
—
—
—
cases:0.00%
controls:1.36%
—
—
0
15
89
875
0
11
89
879
—
—
—
0
12
88
868
—
azathioprine; oral, parenteral
L04AX01 [21603927]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
89
885
—
—
—
—
—
—
No procedures
SPAT1301 [2001700402]
—
—
—
—
—
—
-7.6e-02
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:6.47%
—
—
—
—
—
—
5
55
78
795
Demanding periodontal treatment
SDA04 [2001310329]
—
-1.0e+50
—
—
—
—
4.8e-01
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
cases:8.43%
controls:5.41%
—
0
7
89
883
—
—
—
—
7
46
76
804
Other and unspecified symptoms and signs involving cognitive functions and awareness
R41.8 [45534452]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
0
6
89
884
—
—
—
—
—
0
7
83
843
Bacteria identified in Isolate by Culture
43409-2 [3042936]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
cases:0.00%
controls:2.35%
—
—
—
—
—
0
10
88
870
0
20
83
830
Migraine
G43 [45566873]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
5
83
845
Other hypothyroidism
E03 [45581337]
—
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:0.00%
—
—
—
—
—
—
5
0
78
850
Apolipoprotein B [Mass/volume] in Serum or Plasma
1884-6 [3014791]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
5
83
845
Insect bite/sting
S12 [2002000977]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.53%
—
—
—
—
—
—
0
13
83
837
verapamil; oral, parenteral
C08DA01 [21601767]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
89
885
—
—
—
—
—
—
EKG study
11524-6 [3013512]
—
—
—
—
—
—
1.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:6.59%
—
—
—
—
—
—
6
56
77
794
Campylobacter sp identified in Tissue by Organism specific culture
20740-7 [3006418]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
0
5
89
885
—
—
—
—
—
0
6
83
844
Thorax extensive CT-examination
GD1BD [2001303621]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
89
884
—
—
—
—
—
—
Dental impressions
SBB10 [2001310299]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
89
883
—
—
—
—
—
—
Bacterial infection, unspecified
A49.9 [45590816]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
89
882
—
—
—
—
—
—
Periodontal treatment, brief
SDA02 [2001310327]
—
-1.0e+50
—
—
—
—
4.2e-02
—
—
cases:0.00%
controls:1.46%
—
—
—
—
—
—
—
—
cases:8.43%
controls:8.12%
—
0
13
89
877
—
—
—
—
7
69
76
781
Chronic alcohol abuse
P15 [2002000811]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
5
83
845
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
6
83
844
C peptide [Moles/volume] in Serum or Plasma --fasting
42180-0 [3032836]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
5
83
845
Diaphragmatic hernia without obstruction or gangrene
K44.9 [45533596]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
89
885
—
—
—
—
—
—
Retention of urine
R33 [45587507]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
5
83
845
ferrous glycine sulfate; oral
B03AA01 [21601080]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
89
885
—
—
—
—
—
—
Functional capacity evaluation
443351003 [40481051]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
0
7
89
883
—
—
—
0
8
88
872
—
Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
0
5
89
885
—
—
—
—
—
0
7
83
843
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
4.0e-01
—
—
—
—
-1.0e+50
3.0e-01
cases:6.74%
controls:4.61%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.50%
cases:9.64%
controls:7.29%
6
41
83
849
—
—
—
—
0
22
88
858
8
62
75
788
General symptom/complaint other
A29 [2002000163]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.90%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
cases:0.00%
controls:2.24%
0
8
89
882
—
—
—
—
0
6
88
874
0
19
83
831
Measurement of bone density from two or more locations with X-ray
NK6QA [2001308500]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
0
9
83
841
betamethasone
S03BA03 [21605203]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
0
5
89
885
—
—
—
0
6
88
874
—
combinations of corticosteroids
D07AB30 [21602118]
7.3e-01
—
—
—
—
—
8.0e-01
cases:17.98%
controls:9.55%
—
—
—
—
—
—
—
—
—
—
cases:16.87%
controls:8.35%
16
85
73
805
—
—
—
—
—
14
71
69
779
Health maint/preventive medicine
A98 [2002000231]
-1.3e-02
-8.5e-03
—
—
7.2e-01
8.6e-02
1.3e-01
cases:22.47%
controls:22.70%
cases:15.73%
controls:15.84%
—
—
—
—
cases:5.62%
controls:2.81%
cases:20.45%
controls:19.09%
cases:50.60%
controls:47.41%
20
202
69
688
14
141
75
749
—
—
5
25
84
865
18
168
70
712
42
403
41
447
Limited function/disability (L)
L28 [2002000647]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
17
89
873
—
—
—
—
—
—
orphenadrine, combinations
M03BC51 [21604113]
2.1e-01
—
—
—
—
—
—
cases:5.62%
controls:4.61%
—
—
—
—
—
—
—
—
—
—
—
—
5
41
84
849
—
—
—
—
—
—
pH of Urine
2756-5 [3015736]
5.4e-01
—
—
—
—
6.8e-01
5.4e-01
cases:6.74%
controls:4.04%
—
—
—
—
—
—
—
—
cases:5.68%
controls:2.95%
cases:16.87%
controls:10.59%
6
36
83
854
—
—
—
—
5
26
83
854
14
90
69
760
Periodontitis pronounced
K05.31 [2000502729]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
0
5
89
885
—
—
—
—
0
9
83
841
Immunohistochemistry procedure
117617002 [4035726]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
89
884
—
—
—
—
—
—
Sinus symptom/complaint
R09 [2002000890]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
0
12
83
838
Leg/thigh symptom/complaint
L14 [2002000638]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
89
885
—
—
—
—
—
—
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
—
—
—
—
—
—
—
0
10
88
870
—
Audiology
64 [38004489]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:2.00%
—
—
—
—
—
—
5
17
78
833
hydrocortisone aceponate
D07AC16 [21602135]
5.5e-02
—
—
—
—
—
8.7e-01
cases:6.74%
controls:6.40%
—
—
—
—
—
—
—
—
—
—
cases:12.05%
controls:5.41%
6
57
83
833
—
—
—
—
—
10
46
73
804
pneumococcus, purified polysaccharides antigen conjugated
J07AL02 [21601313]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
0
6
89
884
—
—
—
—
—
0
7
83
843
metronidazole
D06BX01 [21602096]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
89
884
—
—
—
—
—
—
Breast cancer
115 [2001600115]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
89
883
—
—
—
—
—
—
Plantar fascial fibromatosis
M72.2 [45553265]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
0
5
89
885
—
—
—
—
—
0
5
83
845
Health check-up of pregnant person
SPAT1379 [2001700479]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
0
5
88
875
—
Type 2 diabetes mellitus, with unspecified complications
E11.8 [45561951]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.00%
—
0
5
89
885
—
—
—
—
0
17
83
833
triamcinolone and antiseptics
D07BB03 [21602150]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
0
5
89
885
—
—
—
—
—
Bacteria [#/volume] in Urine by Culture
100906-7 [1761482]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
6
83
844
Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
cases:0.00%
controls:1.53%
—
—
—
—
—
0
7
88
873
0
13
83
837
glucosamine; oral
M01AX05 [21604002]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.80%
—
—
—
—
—
—
—
—
—
—
—
0
16
89
874
—
—
—
—
—
Counselling, unspecified
Z71.9 [45561648]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
0
5
88
875
—
Polysomnography panel
90568-7 [1002224]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
6
83
844
zolmitriptan; nasal, oral
N02CC03 [21604378]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
0
10
89
880
—
—
—
—
0
6
88
874
—
Additional procedure necessary for restorative treatment
SFC01 [2001310369]
—
—
—
—
—
—
2.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:4.59%
—
—
—
—
—
—
5
39
78
811
Specific gravity of Urine by Refractometry
5810-7 [3019150]
—
—
—
—
—
—
4.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.64%
controls:6.59%
—
—
—
—
—
—
8
56
75
794
Local application of medicine to mouth
SXA20 [2001310579]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
0
6
89
884
—
—
—
—
—
0
7
83
843
Specific gravity of Urine by Test strip
5811-5 [3000330]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
0
10
83
840
Primary gonarthrosis, bilateral
M17.0 [45562648]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.90%
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
0
8
89
882
0
7
89
883
—
—
—
—
—
Gastroenterology
10 [38004455]
7.3e-01
—
—
—
—
—
9.5e-01
cases:6.74%
controls:3.37%
—
—
—
—
—
—
—
—
—
—
cases:10.84%
controls:4.47%
6
30
83
860
—
—
—
—
—
9
38
74
812
insulin glargine; parenteral
A10AE04 [21600739]
—
—
—
—
—
—
8.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:2.71%
—
—
—
—
—
—
5
23
78
827
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
2.8e-01
1.2e+00
—
—
—
—
—
cases:7.87%
controls:6.07%
cases:5.62%
controls:1.80%
—
—
—
—
—
—
—
—
—
—
7
54
82
836
5
16
84
874
—
—
—
—
—
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
-1.0e+50
—
—
—
—
-1.0e+50
1.3e+00
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
cases:6.02%
controls:1.65%
0
6
89
884
—
—
—
—
0
5
88
875
5
14
78
836
empagliflozin; oral
A10BK03 [1123740]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
cases:0.00%
controls:1.76%
—
—
—
—
—
0
6
88
874
0
15
83
835
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
5
83
845
felodipine; oral
C08CA02 [21601748]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.35%
cases:0.00%
controls:0.90%
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
0
12
89
878
0
8
89
882
—
—
—
0
7
88
873
—
mometasone; nasal
R01AD09 [21605051]
4.7e-01
—
—
—
—
—
6.8e-01
cases:13.48%
controls:8.88%
—
—
—
—
—
—
—
—
—
—
cases:14.46%
controls:7.88%
12
79
77
811
—
—
—
—
—
12
67
71
783
hepatitis vaccines - combinations
J07BC20 [21601340]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
89
885
—
—
—
—
—
—
Appendectomy
JEA00 [2001304802]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
89
884
—
—
—
—
—
—
Derangement of meniscus due to old tear or injury
M23.2 [45591779]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
89
883
—
—
—
—
—
—
clindamycin; oral, parenteral
J01FF01 [21602985]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.64%
controls:2.82%
—
—
—
—
—
—
8
24
75
826
Social worker
Z2446 [2001311559]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
0
5
89
885
—
—
—
—
—
Dysuria/painful urination
U01 [2002001137]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
0
6
88
874
—
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.29%
—
—
—
—
—
—
0
11
83
839
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
0
7
88
873
—
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
7.6e-01
8.3e-01
—
—
2.2e+00
1.0e+00
1.4e-01
cases:6.74%
controls:3.26%
cases:7.87%
controls:3.60%
—
—
—
—
cases:5.62%
controls:0.67%
cases:9.09%
controls:3.52%
cases:13.25%
controls:11.76%
6
29
83
861
7
32
82
858
—
—
5
6
84
884
8
31
80
849
11
100
72
750
Body temperature
8310-5 [3020891]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
6
83
844
ECG with 12 standard connections
XF400 [2001303368]
1.4e+00
—
—
—
—
—
—
cases:5.62%
controls:1.46%
—
—
—
—
—
—
—
—
—
—
—
—
5
13
84
877
—
—
—
—
—
—
fenoterol and ipratropium bromide
R03AL01 [43534843]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
89
884
—
—
—
—
—
—
Resection of other vein
PHD99 [2001309496]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
89
885
—
—
—
—
—
—
Conjunctival surface anesthesia
WX100 [2001310764]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
89
885
—
—
—
—
—
—
Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection
21613-5 [3006093]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
0
7
89
883
—
—
—
—
0
6
88
874
—
IgE [Units/volume] in Serum or Plasma
19113-0 [3005322]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
89
884
—
—
—
—
—
—
Palpitations
R00.2 [45558446]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
0
6
89
884
—
—
—
—
—
0
10
83
840
fluticasone; nasal
R01AD08 [21605050]
6.6e-01
9.0e-01
—
—
—
1.3e+00
8.3e-01
cases:15.73%
controls:8.76%
cases:5.62%
controls:2.36%
—
—
—
—
—
—
cases:7.95%
controls:2.39%
cases:16.87%
controls:8.12%
14
78
75
812
5
21
84
869
—
—
—
7
21
81
859
14
69
69
781
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
4.2e-01
—
—
—
—
—
-3.4e-01
cases:8.99%
controls:6.07%
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:8.24%
8
54
81
836
—
—
—
—
—
5
70
78
780
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: current
SMOKING-1-1-1 [2002330115]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
89
878
—
—
—
—
—
—
norfloxacin; oral
J01MA06 [21603013]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.69%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
89
875
—
—
—
—
—
—
ondansetron; oral, parenteral, rectal
A04AA01 [21600493]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
0
5
89
885
—
—
—
—
0
10
83
840
Removal of sutures from oral mucosa
SXB00 [2001310580]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
0
8
89
882
—
—
—
—
—
0
10
83
840
zolpidem; oral
N05CF02 [21604655]
8.1e-01
—
—
—
—
—
5.6e-01
cases:5.62%
controls:2.58%
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:3.53%
5
23
84
867
—
—
—
—
—
5
30
78
820
Excessive and frequent menstruation with regular cycle
N92.0 [45577544]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
89
882
—
—
—
—
—
—
meloxicam; oral, parenteral, rectal
M01AC06 [21603965]
6.5e-02
-1.0e+50
—
—
—
—
—
cases:5.62%
controls:5.28%
cases:0.00%
controls:1.69%
—
—
—
—
—
—
—
—
—
—
5
47
84
843
0
15
89
875
—
—
—
—
—
prednisolone; oral, parenteral
H02AB06 [21602734]
3.1e-01
1.1e+00
—
—
1.8e+00
9.8e-01
6.7e-01
cases:10.11%
controls:7.64%
cases:10.11%
controls:3.60%
—
—
—
—
cases:6.74%
controls:1.12%
cases:10.23%
controls:4.09%
cases:16.87%
controls:9.41%
9
68
80
822
9
32
80
858
—
—
6
10
83
880
9
36
79
844
14
80
69
770
rosuvastatin; oral
C10AA07 [21601862]
—
—
—
—
—
—
4.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.64%
controls:6.12%
—
—
—
—
—
—
8
52
75
798
naproxen; oral, rectal
M01AE02 [21603968]
3.0e-01
7.3e-01
-1.0e+50
—
—
—
6.8e-02
cases:12.36%
controls:9.44%
cases:6.74%
controls:3.37%
cases:0.00%
controls:0.67%
—
—
—
—
—
—
cases:9.64%
controls:9.06%
11
84
78
806
6
30
83
860
0
6
89
884
—
—
—
8
77
75
773
brompheniramine, combinations
R06AB51 [21603466]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
0
6
89
884
—
—
—
0
6
88
874
—
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
—
1.6e+00
—
—
—
—
4.3e-01
—
—
cases:5.62%
controls:1.24%
—
—
—
—
—
—
—
—
cases:6.02%
controls:4.00%
—
5
11
84
879
—
—
—
—
5
34
78
816
norethisterone and ethinylestradiol
G03AA05 [21602478]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
cases:0.00%
controls:1.14%
cases:0.00%
controls:1.65%
—
0
6
89
884
—
—
—
0
10
88
870
0
14
83
836
tetanus toxoid, combinations with diphtheria toxoid
J07AM51 [21601317]
—
-1.0e+50
—
—
—
—
1.1e+00
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
cases:7.23%
controls:2.47%
—
0
5
89
885
—
—
—
—
6
21
77
829
Bacteria identified in Urine by Culture
630-4 [3026008]
1.4e+00
—
—
—
—
—
2.9e-01
cases:6.74%
controls:1.80%
—
—
—
—
—
—
—
—
—
—
cases:8.43%
controls:6.47%
6
16
83
874
—
—
—
—
—
7
55
76
795
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:1.76%
—
—
—
—
—
—
5
15
78
835
etoricoxib; oral
M01AH05 [21603996]
4.2e-01
—
-1.0e+50
—
-1.0e+50
3.5e-01
3.1e-01
cases:14.61%
controls:10.11%
—
—
cases:0.00%
controls:0.67%
—
—
cases:0.00%
controls:0.67%
cases:6.82%
controls:4.89%
cases:18.07%
controls:13.88%
13
90
76
800
—
0
6
89
884
—
0
6
89
884
6
43
82
837
15
118
68
732
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.56%
cases:0.00%
controls:0.79%
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
0
5
89
885
0
7
89
883
—
—
—
0
5
88
875
—
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.29%
—
—
—
—
—
—
0
11
83
839
Periodontal treatment, very brief
SDA01 [2001310326]
—
-1.0e+50
—
—
—
-1.0e+50
2.6e-01
—
—
cases:0.00%
controls:1.24%
—
—
—
—
—
—
cases:0.00%
controls:1.36%
cases:7.23%
controls:5.65%
—
0
11
89
879
—
—
—
0
12
88
868
6
48
77
802
Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma
70200-1 [42868674]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.12%
cases:0.00%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
0
10
89
880
0
8
89
882
—
—
—
—
—
Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.25%
—
—
0
7
89
883
—
—
—
—
0
11
88
869
—
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
—
—
—
—
—
—
4.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.43%
controls:5.65%
—
—
—
—
—
—
7
48
76
802
Restricted health certificate
SPAT1283 [2001700384]
7.2e-01
—
—
—
—
—
—
cases:5.62%
controls:2.81%
—
—
—
—
—
—
—
—
—
—
—
—
5
25
84
865
—
—
—
—
—
—
Contusion of shoulder and upper arm
S40.0 [45563774]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
5
83
845
Melanocytic naevi of lower limb, including hip
D22.7 [45566673]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
6
83
844
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
3.7e-01
—
—
—
-1.0e+50
—
7.4e-01
cases:5.62%
controls:3.93%
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
cases:18.07%
controls:9.53%
5
35
84
855
—
—
—
0
5
89
885
—
15
81
68
769
denosumab; parenteral
M05BX04 [21604169]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
cases:0.00%
controls:1.18%
—
—
—
—
—
0
6
88
874
0
10
83
840
Emergency visit or other similar visit involving procedures
WYA05 [2001310871]
-2.9e-01
—
—
—
—
—
5.4e-02
cases:10.11%
controls:13.03%
—
—
—
—
—
—
—
—
—
—
cases:9.64%
controls:9.18%
9
116
80
774
—
—
—
—
—
8
78
75
772
Old myocardial infarction
I25.2 [45601025]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
0
5
89
885
—
—
—
—
—
0
5
83
845
fluorometholone
S01BA07 [21603624]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
89
883
—
—
—
—
—
—
isotretinoin; oral
D10BA01 [21602320]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
0
7
83
843
insulin (beef); parenteral
A10AD02 [21600730]
—
—
—
—
—
—
8.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:2.71%
—
—
—
—
—
—
5
23
78
827
Sinusitis acute/chronic
R75 [2002000943]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
89
882
—
—
—
—
—
—
Pregnancy associated plasma protein A [Multiple of the median] adjusted in Serum or Plasma
76348-2 [46235831]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
0
8
83
842
Base excess in Venous blood by calculation
1927-3 [3002032]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
0
7
88
873
—
palonosetron, combinations
A04AA55 [45893275]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
5
83
845
Functional dyspepsia
K30 [45591584]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.29%
—
—
—
—
—
—
0
11
83
839
glimepiride; oral
A10BB12 [21600761]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
cases:0.00%
controls:0.80%
cases:0.00%
controls:0.94%
—
0
9
89
881
—
—
—
0
7
88
873
0
8
83
842
telmisartan and diuretics
C09DA07 [21601839]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
0
5
89
885
—
—
—
—
—
0
5
83
845
Elevated blood pressure
K85 [2002000612]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
0
6
88
874
—
Student oral health check consistent with decree to assess need for oral health guidance and services
WYA50 [2001310877]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
89
885
—
—
—
—
—
—
Irregular heartbeat other
K05 [2002000548]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
5
83
845
Chronic ischaemic heart disease, unspecified
I25.9 [45552784]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
89
885
—
—
—
—
—
—
Other specified special examinations
Z01.8 [45581003]
9.0e-01
—
—
—
—
—
—
cases:5.62%
controls:2.36%
—
—
—
—
—
—
—
—
—
—
—
—
5
21
84
869
—
—
—
—
—
—
Dental examination
Z01.2 [45581002]
5.2e-01
—
—
—
—
—
-2.4e-01
cases:7.87%
controls:4.83%
—
—
—
—
—
—
—
—
—
—
cases:8.43%
controls:10.47%
7
43
82
847
—
—
—
—
—
7
89
76
761
Cathetrisation of vein
TPH04 [2001309597]
1.6e+00
—
—
—
—
—
1.2e+00
cases:5.62%
controls:1.24%
—
—
—
—
—
—
—
—
—
—
cases:8.43%
controls:2.71%
5
11
84
879
—
—
—
—
—
7
23
76
827
Fracture of metatarsal bone
S92.3 [45574912]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
89
885
—
—
—
—
—
—
Periodontal treatment
SDA03 [2001310328]
—
—
—
—
—
—
-4.8e-03
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.43%
controls:8.47%
—
—
—
—
—
—
7
72
76
778
Albumin [Mass/time] in Urine collected for unspecified duration
49002-9 [3050449]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
0
7
83
843
Periodontitis NOS
K05.32 [2000502730]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
89
882
—
—
—
—
—
—
Irrigation or wax removal of outer auditory canal
SPAT1033 [2001700134]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
0
9
88
871
—
Chronic apical periodontitis
K04.5 [45586691]
—
—
—
—
—
-1.0e+50
5.1e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
cases:7.23%
controls:4.47%
—
—
—
—
—
0
10
88
870
6
38
77
812
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
—
—
—
—
—
1.3e+00
5.7e-01
—
—
—
—
—
—
—
—
—
—
cases:6.82%
controls:2.05%
cases:14.46%
controls:8.71%
—
—
—
—
—
6
18
82
862
12
74
71
776
Sequelae of cerebral infarction
I69.3 [45533476]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
0
9
83
841
Diarrhoea
D11 [2002000310]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
0
7
89
883
—
—
—
—
—
nortriptyline; oral, parenteral
N06AA10 [21604697]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
0
5
89
885
—
—
—
—
—
0
6
83
844
Venereal disease screening
171128005 [4064905]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
89
885
—
—
—
—
—
—
Contraception intrauterine
W12 [2002001212]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
89
880
—
—
—
—
—
—
Sensorineural hearing loss, unilateral with unrestricted hearing on the contralateral side
H90.4 [45572067]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
5
83
845
Creatine kinase.MB [Mass/volume] in Serum or Plasma
13969-1 [3005785]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
0
6
89
884
—
—
—
—
0
5
88
875
—
Release of median nerve
ACC51 [2001300642]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
0
10
83
840
Periodontal treatment by dental hygienist, very extensive
SDE04 [2001310352]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
0
6
89
884
—
—
—
—
—
Fracture of lower end of radius
S52.5 [45573842]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
89
879
—
—
—
—
—
—
Pregnancy confirmed
Z32.1 [45566418]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
0
8
88
872
—
Osteoporosis
L95 [2002000714]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
6
83
844
Monocytes [#/volume] in Blood
26484-6 [3001604]
9.3e-01
8.9e-01
—
—
2.2e+00
1.3e+00
2.1e-01
cases:7.87%
controls:3.26%
cases:7.87%
controls:3.37%
—
—
—
—
cases:5.62%
controls:0.67%
cases:10.23%
controls:3.07%
cases:14.46%
controls:12.00%
7
29
82
861
7
30
82
860
—
—
5
6
84
884
9
27
79
853
12
102
71
748
Basophils [#/volume] in Blood
26444-0 [3006315]
9.3e-01
8.9e-01
—
—
2.2e+00
1.3e+00
1.2e-01
cases:7.87%
controls:3.26%
cases:7.87%
controls:3.37%
—
—
—
—
cases:5.62%
controls:0.67%
cases:10.23%
controls:3.07%
cases:13.25%
controls:11.88%
7
29
82
861
7
30
82
860
—
—
5
6
84
884
9
27
79
853
11
101
72
749
Biopsy of vaginal cervix
LDA20 [2001306656]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
89
883
—
—
—
—
—
—
Electrocardiogram with exercise test
46136006 [4261794]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
0
5
89
885
—
—
—
—
—
tibolone; oral
G03CX01 [21602536]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
0
6
89
884
—
—
—
—
—
0
5
83
845
Organisation of medication
SPAT1251 [2001700352]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
89
884
—
—
—
—
—
—
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
—
-1.0e+50
—
—
—
—
9.3e-01
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
cases:6.02%
controls:2.47%
—
0
9
89
881
—
—
—
—
5
21
78
829
dexbrompheniramine, combinations
R06AB56 [21603469]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
0
5
88
875
—
Vertigo/dizziness
N17 [2002000728]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
0
8
83
842
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
—
—
—
—
—
—
7.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.64%
controls:4.71%
—
—
—
—
—
—
8
40
75
810
Contusion of other parts of wrist and hand
S60.2 [45602941]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
0
6
89
884
—
—
—
—
—
0
6
83
844
Perimetry
XCK00 [2001301380]
1.6e+00
—
—
—
—
—
—
cases:5.62%
controls:1.24%
—
—
—
—
—
—
—
—
—
—
—
—
5
11
84
879
—
—
—
—
—
—
chondroitin sulfate
M01AX25 [21604013]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.46%
cases:0.00%
controls:0.90%
—
—
—
—
cases:0.00%
controls:0.67%
cases:0.00%
controls:0.91%
cases:0.00%
controls:1.65%
0
13
89
877
0
8
89
882
—
—
0
6
89
884
0
8
88
872
0
14
83
836
temazepam; oral
N05CD07 [21604642]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:1.01%
cases:0.00%
controls:0.56%
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
0
9
89
881
0
5
89
885
—
0
5
89
885
—
—
Clinic/Center
261Q00000X [38004207]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
89
884
—
—
—
—
—
—
tranexamic acid; oral, parenteral
B02AA02 [21601036]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
0
5
88
875
—
Screening procedure
SPAT1324 [2001700425]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
0
10
89
880
—
—
—
0
9
88
871
—
Alzheimer disease with late onset
G30.1 [45552521]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
6
83
844
Supervision of normal pregnancy
Z34 [45566419]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
5
83
845
Sciatica
M54.3 [45586994]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
5
83
845
fluocortolone
D07AC05 [21602124]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.06%
0
8
89
882
—
—
—
—
—
0
9
83
841
Extensive examination of musculoskeletal system
SPAT1212 [2001700313]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
0
9
83
841
Cardiac arrhythmia, unspecified
I49.9 [45581778]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:1.41%
—
—
—
—
—
—
5
12
78
838
Trichilemmal cyst
L72.1 [45596386]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
89
884
—
—
—
—
—
—
Dysthyroid exophthalmos and Thyrotoxicosis with diffuse goitre
H06.2*E05.0 [2000503914]
—
1.0e+50
—
—
—
1.0e+50
—
—
—
cases:6.74%
controls:0.00%
—
—
—
—
—
—
cases:7.95%
controls:0.00%
—
—
—
6
0
83
890
—
—
—
7
0
81
880
—
levonorgestrel
G03AC03 [21602499]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
0
7
88
873
—
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
—
—
—
—
—
—
9.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.25%
controls:5.76%
—
—
—
—
—
—
11
49
72
801
Dental calculus supragingival
K03.64 [2000502689]
6.0e-01
—
—
—
—
—
—
cases:5.62%
controls:3.15%
—
—
—
—
—
—
—
—
—
—
—
—
5
28
84
862
—
—
—
—
—
—
Atrial premature depolarization
I49.1 [45552795]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
0
7
83
843
Low back symptom/complaint
L03 [2002000628]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
0
6
88
874
—
Open wound of wrist and hand, part unspecified
S61.9 [45554740]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
6
83
844
Check up of cardiac pacemaker
XFP20 [2001303367]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:0.82%
—
—
—
—
—
—
5
7
78
843
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
-1.4e-01
—
—
—
—
—
7.6e-01
cases:5.62%
controls:6.40%
—
—
—
—
—
—
—
—
—
—
cases:12.05%
controls:6.00%
5
57
84
833
—
—
—
—
—
10
51
73
799
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
2.0e-01
-3.2e-01
—
—
1.3e+00
-3.3e-01
-5.3e-02
cases:37.08%
controls:32.58%
cases:12.36%
controls:16.29%
—
—
—
—
cases:7.87%
controls:2.25%
cases:11.36%
controls:15.11%
cases:37.35%
controls:38.59%
33
290
56
600
11
145
78
745
—
—
7
20
82
870
10
133
78
747
31
328
52
522
orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]
4.2e-01
—
—
—
—
—
-3.4e-01
cases:8.99%
controls:6.07%
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:8.24%
8
54
81
836
—
—
—
—
—
5
70
78
780
Nonallergic asthma
J45.1 [45557625]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
0
5
89
885
—
—
—
—
—
Parabulbar anesthesia
WX140 [2001310772]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
89
885
—
—
—
—
—
—
ketotifen
S01GX08 [21605092]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
0
5
89
885
—
—
—
—
0
5
83
845
Moderate depressive episode
F32.1 [45552478]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
89
885
—
—
—
—
—
—
Ear microscopy
UDC00 [2001301558]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.06%
—
—
—
—
—
—
0
9
83
841
ofloxacin; oral, parenteral
J01MA01 [21603008]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
5
83
845
Acute inflammatory disease of uterus
N71.0 [45596880]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
5
83
845
Acute bronchitis
J20 [45581849]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.41%
—
—
—
—
—
—
0
12
83
838
Bicarbonate [Moles/volume] standard in Capillary blood
19231-0 [3004490]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
5
83
845
pregabalin; oral
N02BF02 [955152]
—
-1.0e+50
—
—
-1.0e+50
-1.0e+50
2.9e-01
—
—
cases:0.00%
controls:1.35%
—
—
—
—
cases:0.00%
controls:0.56%
cases:0.00%
controls:1.70%
cases:6.02%
controls:4.59%
—
0
12
89
878
—
—
0
5
89
885
0
15
88
865
5
39
78
811

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
21
42
6.24
10.66
1.5
1.2
328.76
49.43
u/ml
1.43
11
17
59
384
2.59
4.33
7.8
6.1
1.21
1.22
mmol/l
0.29
51
330
42
242
2.39
3.91
4.0
3.7
7.41
7.40
ph
0.37
33
168
50
330
2.18
3.19
4.1
3.7
35.88
36.13
g/l
0.11
44
316
22
105
2.45
3.00
1.4
1.7
893.63
1348.34
nmol/l
2.44
22
77
34
197
2.17
2.97
1.4
1.2
1.22
1.98
u/ml
—
6
53
52
372
1.96
2.44
8.0
5.4
8.17
8.19
%
0.01
47
355
53
382
1.96
2.43
8.2
5.4
25.88
27.35
%
0.37
48
369
30
181
1.99
2.28
1.5
1.3
2.10
2.17
g/l
0.13
19
111
47
332
1.88
2.22
2.0
1.9
99.35
95.71
pmol/l
0.21
17
160
51
370
1.89
2.22
8.2
5.4
0.72
0.67
%
0.26
46
345
51
370
1.89
2.22
8.1
5.4
2.72
2.69
%
0.04
46
351
60
464
1.90
2.09
10.7
10.5
4.11
4.19
e9/l
0.08
54
406
36
240
1.84
2.00
5.5
7.3
—
—
—
0
0
37
250
1.82
1.96
7.9
5.3
—
—
—
0
0
50
373
1.78
1.88
8.3
5.3
57.70
58.29
%
0.12
45
359
16
82
2.16
1.83
1.4
1.2
—
—
—
0
0
14
68
2.26
1.82
3.1
2.7
1.84
1.65
%
0.27
14
63
53
407
1.75
1.76
8.0
5.9
0.58
0.55
e9/l
0.38
46
358
7
26
2.83
1.61
2.3
1.6
219.34
214.41
ug/l
—
7
21
24
151
1.81
1.56
1.2
1.4
53.03
9.86
u/ml
—
7
56
52
407
1.67
1.53
8.1
5.9
0.04
0.04
e9/l
0.08
45
356
22
136
1.82
1.51
6.0
3.0
50.21
75.91
ng/l
0.21
14
92
13
69
2.04
1.37
1.7
1.4
—
—
—
0
0
12
62
2.08
1.35
1.2
1.1
—
—
—
0
0
9
43
2.21
1.35
2.7
1.4
—
—
—
0
0
34
248
1.60
1.27
2.4
3.2
—
0.00
—
0
6
28
198
1.60
1.18
3.1
3.8
—
—
—
0
0
64
549
1.59
1.13
4.1
4.3
—
—
—
0
0
5
21
2.46
1.10
1.2
1.2
—
—
—
0
0
42
332
1.50
1.06
2.1
1.9
—
—
—
0
0
44
353
1.49
1.03
2.7
3.4
6.21
6.18
ph
0.06
19
200
0
28
0.00
0.99
0.0
4.2
—
37.02
—
0
28
6
27
2.31
0.95
1.0
1.3
—
—
—
0
0
43
350
1.44
0.90
12.6
12.1
0.00
0.00
e9/l
0.50
35
287
14
89
1.68
0.87
1.8
1.6
—
—
—
0
0
8
45
1.85
0.87
1.6
1.2
—
—
—
0
0
35
277
1.43
0.84
3.2
3.7
35.72
26.16
ng/l
0.33
24
188
8
47
1.77
0.83
1.0
1.1
—
—
—
0
0
0
24
0.00
0.80
0.0
1.2
—
2.18
—
0
17
0
25
0.00
0.80
0.0
1.3
—
22.11
—
0
19
51
435
1.40
0.80
3.1
3.9
0.00
0.00
estimate
—
9
96
24
180
1.46
0.76
1.7
1.6
1.25
1.45
mg/l
0.10
19
148
51
440
1.37
0.72
3.1
3.9
0.00
0.00
estimate
—
9
88
33
266
1.38
0.70
2.0
2.0
—
—
—
0
0
50
432
1.36
0.69
3.1
3.9
0.00
0.00
estimate
—
8
96
0
22
0.00
0.60
0.0
1.3
—
—
—
0
0
12
82
1.54
0.58
1.3
1.5
—
—
—
0
0
77
722
1.49
0.57
6.4
6.0
38.17
38.67
mmol/mol
0.24
72
683
83
790
1.75
0.55
16.9
13.7
20.57
22.28
mg/l
0.18
70
634
29
243
1.29
0.46
3.6
3.5
—
—
—
0
0
50
449
1.26
0.45
5.6
4.3
6.46
6.55
mmol/l
0.15
50
427
13
96
1.41
0.44
1.6
1.4
—
—
—
0
0
21
169
1.32
0.44
1.2
1.4
9.30
24.28
iu/ml
—
5
66
0
15
0.00
0.41
0.0
1.2
—
—
—
0
0
6
44
1.39
0.35
12.8
6.8
25.33
25.03
mmol/l
—
6
44
13
101
1.34
0.34
1.8
1.5
—
—
—
0
0
17
206
0.78
0.34
8.1
5.1
—
—
—
0
0
29
252
1.22
0.33
3.3
3.3
0.00
0.01
estimate
—
6
78
7
56
1.27
0.30
11.9
6.4
—
—
—
0
0
5
71
0.69
0.27
1.0
1.8
—
0.00
estimate
—
0
20
8
101
0.77
0.22
1.4
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
31.17
—
0
12
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
6
47
1.30
0.21
14.0
4.8
22.75
24.74
mmol/l
—
6
47
0
13
0.00
0.21
0.0
3.5
—
108.15
—
0
13
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
3.5
—
3.90
—
0
13
0
13
0.00
0.21
0.0
3.5
—
1.19
—
0
13
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
8
72
1.12
0.16
3.9
3.4
—
—
—
0
0
40
376
1.12
0.15
2.6
2.6
—
—
estimate
—
0
0
9
105
0.84
0.14
1.3
1.2
—
—
—
0
0
21
228
0.90
0.11
2.6
2.8
0.59
0.41
e6/l
0.24
14
160
10
86
1.18
0.11
1.7
1.8
—
—
—
0
0
25
232
1.11
0.11
3.4
2.9
10.76
44.98
mg/l
1.67
17
146
36
343
1.08
0.09
3.5
3.6
0.00
0.00
estimate
—
7
84
12
107
1.14
0.09
1.3
1.2
—
—
—
0
0
15
164
0.90
0.08
2.3
2.0
—
—
—
0
0
20
186
1.10
0.08
3.4
3.6
1.02
1.02
kg/l
0.00
12
119
20
214
0.92
0.08
2.7
2.8
—
—
estimate
—
0
0
37
355
1.07
0.07
2.0
1.9
1.33
1.32
mmol/l
0.03
31
299
82
806
1.22
0.07
17.1
12.2
—
—
—
0
0
66
673
0.93
0.07
26.3
17.4
13.42
13.62
%
0.88
66
663
13
141
0.91
0.06
1.7
1.6
—
—
—
0
0
25
238
1.07
0.05
4.0
3.5
1.61
8.89
mg/mmol
1.69
18
143
23
242
0.93
0.05
1.3
1.6
—
—
—
0
0
16
171
0.92
0.05
2.6
2.6
5.40
6.04
e6/l
0.12
16
158
31
322
0.94
0.05
2.8
3.1
—
—
—
0
0
22
229
0.95
0.03
3.3
3.8
0.00
0.00
estimate
—
9
89
25
257
0.96
0.01
2.8
3.0
—
—
—
0
0
11
108
1.02
0.00
1.9
1.9
—
—
—
0
0
25
255
0.97
0.00
2.7
3.1
52.27
44.93
e6/l
0.08
19
188
10
95
1.06
0.00
7.9
6.4
107.20
104.16
mmol/l
—
10
95
30
296
1.02
0.00
3.0
4.0
29.64
67.55
e6/l
0.35
19
201
0
6
0.00
0.00
0.0
1.0
—
7.32
—
0
6
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
4.7
—
0.83
—
0
6
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.3
—
71.50
—
0
6
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
2.2
—
11.27
—
0
6
0
6
0.00
0.00
0.0
1.2
—
31.68
—
0
6
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.2
—
10.84
—
0
9
0
5
0.00
-0.00
0.0
12.6
—
1038.80
—
0
5
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.2
—
2110.00
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
3.36
—
0
5
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
223.76
—
0
5
6
61
0.98
-0.00
1.5
1.2
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint E4_THYCRISIS and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have E4_THYCRISIS.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

↥

Index endpoint: E4_THYCRISIS – Thyroid crisis or storm

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data